The Application of Soluble Triggering Receptor Expressed on Myeloid Cells-1 in Sepsis & Relevant Acute Kidney Injuries
|ClinicalTrials.gov Identifier: NCT01333657|
Recruitment Status : Completed
First Posted : April 12, 2011
Last Update Posted : August 3, 2011
Triggering receptor expressed on myeloid cells-1 is a member of the immunoglobulin superfamily of receptors that is specifically expressed on the surfaces of monocytes and neutrophils.TREM-1 expression is increased in infectious diseases and is associated with the release of soluble TREM-1 (sTREM-1).There has been demonstrated that the value of plasma sTREM-1 levels as an indicator of sepsis was superior, although other studies reported that the value of sTREM-1 for diagnosing sepsis was inferior.An increasing number of studies indicate that there are increased levels of sTREM-1 in body fluid samples for the following diseases and conditions: sepsis, pneumonia, pleural effusion, septic arthritis, meningitis, peritonitis, and uterine cavity infection.
Inflammation is now believed to play a major role in the pathophysiology of AKI. It is hypothesized that the initial insult results in morphological and/or functional changes in vascular endothelial cells and/or in tubular epithelium in sepsis models. Then, leukocytes including neutrophils, macrophages, natural killer cells, and lymphocytes infiltrate into the injured kidneys and induce the generation of inflammatory mediators. Whether urine sTREM-1 could also be detected and its significance in sepsis and AKI has not been reported yet.
The present study focused on the value of serum & urine sTREM-1 for sepsis identification, severity and prognosis assessments, and potential sepsis-related AKI. We also made comparisons between sTREM-1 and WBC counts, serum CRP, serum PCT, urine output,CC SCr, and BUN among sepsis patients.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||104 participants|
|Official Title:||A Prospective Study on the Diagnosis, Severity and Prognosis of Soluble Triggering Receptor Expressed on Myeloid Cells-1 in Sepsis & Related Complications|
|Study Start Date :||May 2010|
|Actual Primary Completion Date :||April 2011|
|Actual Study Completion Date :||April 2011|
- Patients Outcome [ Time Frame: 28 days ]The survival time of patients more than 28days is defined as survival. The survival time of patients less than 28days is defined as death.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01333657
|Chinese PLA General Hospital|
|Study Director:||Xie Lixin, Doctor||Pneumology Department of chinese PLA General Hospital|